Agomab announces positive phase 2a interim results for AGMB-129
10th March 2025 Uncategorised 0
FSCD therapy meets all endpoints in interim analysis

More: Agomab announces positive phase 2a interim results for AGMB-129
Source: News
FSCD therapy meets all endpoints in interim analysis

More: Agomab announces positive phase 2a interim results for AGMB-129
Source: News
© 1994 - 2026 B.M. Pharmaceuticals